TipRanks
Advertisement
Advertisement

HK:6938 Stock Latest News

Suzhou Ribo Life Science Gains Hang Seng Index, Stock Connect Access
Company AnnouncementsSuzhou Ribo Life Science Gains Hang Seng Index, Stock Connect Access
29d ago
6938
Suzhou Ribo Swings to Profit on Surging Licensing Revenue From RNAi Collaborations
PremiumCompany Announcements
Suzhou Ribo Swings to Profit on Surging Licensing Revenue From RNAi Collaborations
1M ago
6938
Suzhou Ribo Schedules Board Meeting to Approve 2026 Interim Results and Consider Dividend
PremiumCompany Announcements
Suzhou Ribo Schedules Board Meeting to Approve 2026 Interim Results and Consider Dividend
2M ago
6938
Suzhou Ribo forecasts sharp revenue surge on siRNA licensing deals
PremiumCompany Announcements
Suzhou Ribo forecasts sharp revenue surge on siRNA licensing deals
2M ago
6938
Suzhou Ribo Wins EMA Nod for Phase 2b Trial of FXI siRNA Anticoagulant
PremiumCompany Announcements
Suzhou Ribo Wins EMA Nod for Phase 2b Trial of FXI siRNA Anticoagulant
2M ago
6938
Suzhou Ribo Reports First Global Proof-of-Concept for siRNA FXI Therapy in CAD
PremiumCompany AnnouncementsSuzhou Ribo Reports First Global Proof-of-Concept for siRNA FXI Therapy in CAD
3M ago
6938
Suzhou Ribo Life Science Signals Confidence With HK$9.3 Million Share Buyback
Premium
Company Announcements
Suzhou Ribo Life Science Signals Confidence With HK$9.3 Million Share Buyback
3M ago
6938
Suzhou Ribo Executive Boosts Stake in H Shares, Signalling Confidence in Growth Prospects
Premium
Company Announcements
Suzhou Ribo Executive Boosts Stake in H Shares, Signalling Confidence in Growth Prospects
3M ago
6938
Suzhou Ribo Executive Director Increases Stake in H Shares
PremiumCompany Announcements
Suzhou Ribo Executive Director Increases Stake in H Shares
3M ago
6938
Suzhou Ribo Hits First Milestone in Madrigal siRNA Liver Disease Partnership
PremiumCompany Announcements
Suzhou Ribo Hits First Milestone in Madrigal siRNA Liver Disease Partnership
3M ago
6938
Suzhou Ribo Moves to Fully Align Azemidite Stake with RMB70 Million Buyout
PremiumCompany Announcements
Suzhou Ribo Moves to Fully Align Azemidite Stake with RMB70 Million Buyout
3M ago
6938
Suzhou Ribo Life Science Unveils Dual H-Share Purchase and Buyback Plan
PremiumCompany Announcements
Suzhou Ribo Life Science Unveils Dual H-Share Purchase and Buyback Plan
4M ago
6938
Suzhou Ribo Shareholders Clear All Resolutions at 2025 AGM
PremiumCompany AnnouncementsSuzhou Ribo Shareholders Clear All Resolutions at 2025 AGM
4M ago
6938
Suzhou Ribo Advances CAD siRNA Drug With EMA Phase II Filing
Premium
Company Announcements
Suzhou Ribo Advances CAD siRNA Drug With EMA Phase II Filing
4M ago
6938
Suzhou Ribo Reschedules AGM and Adjusts H Share Register Closure
Premium
Company Announcements
Suzhou Ribo Reschedules AGM and Adjusts H Share Register Closure
5M ago
6938
Suzhou Ribo Life Science Sets AGM to Vote on Governance, Share Incentives and New Issuance Mandate
PremiumCompany Announcements
Suzhou Ribo Life Science Sets AGM to Vote on Governance, Share Incentives and New Issuance Mandate
5M ago
6938
Suzhou Ribo Advances Vortosiran With EMA Filing for Phase 2b VTE Trial
PremiumCompany Announcements
Suzhou Ribo Advances Vortosiran With EMA Filing for Phase 2b VTE Trial
5M ago
6938
Suzhou Ribo Hits Third Milestone in Boehringer Ingelheim Liver Disease Collaboration
PremiumCompany Announcements
Suzhou Ribo Hits Third Milestone in Boehringer Ingelheim Liver Disease Collaboration
5M ago
6938
Suzhou Ribo Advances Lead siRNA Anticoagulant With EMA Phase 2b Filing
PremiumCompany Announcements
Suzhou Ribo Advances Lead siRNA Anticoagulant With EMA Phase 2b Filing
6M ago
6938
Suzhou Ribo Life Science Plans New H-Share Incentive Schemes for Staff and Partners
PremiumCompany AnnouncementsSuzhou Ribo Life Science Plans New H-Share Incentive Schemes for Staff and Partners
6M ago
6938
Suzhou Ribo Moves to Streamline Governance and Scrap Supervisory Committee
Premium
Company Announcements
Suzhou Ribo Moves to Streamline Governance and Scrap Supervisory Committee
6M ago
6938
Suzhou Ribo Life Science Widens Loss as Listing Costs Rise Despite Revenue Growth
Premium
Company Announcements
Suzhou Ribo Life Science Widens Loss as Listing Costs Rise Despite Revenue Growth
6M ago
6938

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >